CGC
Canopy Growth Corporation
NASDAQ · Healthcare · Drug Manufacturers - Specialty & Generic · CA
$0.97
−0.02%Income statement
| Metric | TTM | 2026 | 2025 | 2024 | 2023 |
|---|---|---|---|---|---|
| Revenue | |||||
| Total Revenue | 321.4M | 284.6M | 269.0M | 297.1M | 333.3M |
| Cost of Revenue | 239.5M | 214.9M | 189.5M | 216.3M | 396.8M |
| Gross Profit | 81.9M | 69.7M | 79.5M | 80.9M | (63.5M) |
| Operating Expenses | |||||
| R&D Expense | — | — | — | 4.6M | 21.7M |
| SG&A Expense | 143.8M | 122.9M | 121.7M | 180.6M | 298.0M |
| General & Admin Expense | 50.4M | 59.8M | 60.9M | 104.4M | 160.6M |
| Selling & Marketing Expense | 53.2M | 63.1M | 60.9M | 76.1M | 137.3M |
| Other Expenses | 40.7M | 19.9M | 74.9M | 124.4M | 2.2B |
| Total Operating Expenses | 184.5M | 142.8M | 196.7M | 309.6M | 2.6B |
| Cost and Expenses | 424.0M | 357.7M | 386.1M | 525.9M | 3.0B |
| Operating Income (EBIT) | (102.6M) | (73.1M) | (117.1M) | (228.7M) | (2.6B) |
| Non-Operating | |||||
| Interest Income | 13.3M | 10.0M | 8.8M | 16.2M | 24.3M |
| Interest Expense | 43.9M | 38.2M | 74.6M | 105.4M | 126.2M |
| Net Interest Income | (30.5M) | (28.2M) | (65.8M) | (89.1M) | (101.9M) |
| Other Non-Op Income/Expense | (156.9M) | (189.8M) | (479.9M) | (242.6M) | (455.6M) |
| Non-Operating Income (excl Interest) | 125.7M | 151.6M | 405.3M | 137.3M | 329.5M |
| EBT (Pre-Tax Income) | (259.5M) | (262.9M) | (597.0M) | (471.4M) | (3.1B) |
| Income Tax Expense | (260.1K) | 23.0K | 7.1M | 12.3M | (5.7M) |
| Bottom Line | |||||
| Net Income | (259.3M) | (262.9M) | (598.1M) | (657.3M) | (3.3B) |
| Earnings from Cont. Ops | (259.3M) | (262.9M) | (604.1M) | (483.7M) | (3.1B) |
| Earnings from Discont. Ops | — | — | 6.0M | (192.1M) | (229.1M) |
| Bottom Line Net Income | (259.2M) | (262.9M) | (598.1M) | (657.3M) | (3.3B) |
| Per Share | |||||
| Basic EPS | ($0.69) | ($0.88) | ($5.53) | ($8.79) | ($70.70) |
| Diluted EPS | ($0.69) | ($0.88) | ($5.53) | ($8.79) | ($70.70) |
| Revenue Per Share | $0.76 | $0.10 | $2.50 | $3.97 | $7.19 |
| Shares | |||||
| Basic Shares Outstanding | 422.3M | 3.0B | 107.6M | 74.8M | 46.4M |
| Diluted Shares Outstanding | 422.3M | 3.0B | 107.6M | 74.8M | 46.4M |
| Profitability Metrics | |||||
| EBITDA | (188.2M) | (188.2M) | (479.3M) | (312.8M) | (2.9B) |
| D&A | 40.2M | 36.5M | 43.1M | 53.2M | 80.0M |
| EBIT | (228.3M) | (224.7M) | (522.4M) | (366.0M) | (3.0B) |
As reported, in the filing currency · TTM sums the four latest quarters; MRQ is the latest quarter · Negatives in parentheses; a dash is a line the filing does not carry · Data as of Jun 1, 2026